122
Participants
Start Date
February 28, 2013
Primary Completion Date
January 31, 2014
Study Completion Date
March 31, 2014
Rotigotine
"Rotigotine, transdermal patches:~10 cm\^2 (2 mg / 24 hours); 20 cm\^2 (4 mg / 24 hours); 30 cm\^2 (6 mg / 24 hours); 40 cm\^2 (8 mg / 24 hours)~The maximum Rotigotine dose allowed is 8 mg / 24 hours or 16 mg / 24 hours for patients with advanced Parkinson's Disease and 6 mg / 24 hours or 8 mg / 24 hours for those with early Parkinson's Disease Duration: up to 21 weeks (including de-escalation)"
Placebo
"Placebo, matching transdermal patches~Duration: up to 21 weeks (including de-escalation)"
4320, Birmingham
4309, Oxnard
4306, Ormond Beach
4311, Palm Beach Gardens
4313, Tampa
4314, Decatur
4318, Chicago
4316, Winfield
4322, Des Moines
4304, Kansas City
4326, Springfield
4330, Ocean Springs
4302, Las Vegas
4303, Commack
4317, New York
4323, New York
4319, Asheville
4325, Charlotte
4329, Akron
4312, Cincinnati
4324, Beaufort
4332, Charleston
4305, San Antonio
4307, Salt Lake City
4333, Virginia Beach
3001, Innsbruck
3003, Linz
3301, Budapest
3302, Debrecen
3509, Gdansk
3506, Gdynia
3504, Poznan
3801, Banská Bystrica
3805, Bratislava
3806, Krompachy
3807, Žilina
3901, Ljubljana
4001, Barcelona
4006, Barcelona
4009, Oviedo
4005, Seville
4010, Seville
UCB BIOSCIENCES GmbH
INDUSTRY